Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MCRB Seres Therapeutics	$11.60 +6.9%	$8.34	$6.53 ▼ $30.60	$94.75M	2.75	132,566 shs	75,914 shs
NGNE Neurogene	$20.28 +4.0%	$18.01	$6.88 ▼ $74.49	$278.11M	1.51	251,271 shs	97,316 shs
RNAC Cartesian Therapeutics	$11.30 +4.9%	$10.38	$8.46 ▼ $26.50	$279.53M	0.36	100,096 shs	27,919 shs
TERN Terns Pharmaceuticals	$4.53 +13.3%	$3.52	$1.87 ▼ $11.40	$349.35M	-0.11	1.47 million shs	1.42 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MCRB Seres Therapeutics	+6.91%	+8.41%	+40.95%	+8.21%	-40.40%
NGNE Neurogene	+4.00%	+5.68%	-7.10%	+124.58%	-44.88%
RNAC Cartesian Therapeutics	+4.92%	+3.76%	+2.45%	-0.53%	-32.82%
TERN Terns Pharmaceuticals	+13.25%	+17.66%	+22.43%	+96.96%	-39.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MCRB Seres Therapeutics	3.5395 of 5 stars	2.9	2.0	4.6	2.8	0.8	0.0
NGNE Neurogene	3.6125 of 5 stars	4.4	3.0	0.0	1.8	1.7	1.3
RNAC Cartesian Therapeutics	1.4099 of 5 stars	3.4	0.0	0.0	0.6	3.3	0.0
TERN Terns Pharmaceuticals	3.6991 of 5 stars	3.3	1.0	4.1	1.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MCRB Seres Therapeutics	1.75	Reduce	$73.67	535.06% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	127.65% Upside
RNAC Cartesian Therapeutics	2.80	Moderate Buy	$40.67	259.88% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	244.92% Upside

Current Analyst Ratings Breakdown

Latest MCRB, NGNE, TERN, and RNAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	NGNE Neurogene	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$38.00 ➝ $24.00
5/13/2025	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
5/13/2025	TERN Terns Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $15.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
5/8/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$41.00 ➝ $40.00
4/21/2025	TERN Terns Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
4/14/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $16.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MCRB Seres Therapeutics	$126.32M	0.80	N/A	N/A	$1.61 per share	7.20
NGNE Neurogene	$930K	310.96	N/A	N/A	$20.89 per share	0.97
RNAC Cartesian Therapeutics	$38.91M	7.54	N/A	N/A	($0.27) per share	-41.85
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	N/A	N/A	-7.01%	8/6/2025 (Estimated)
TERN Terns Pharmaceuticals	-$88.85M	-$1.09	N/A	N/A	N/A	N/A	-28.81%	-27.55%	8/4/2025 (Estimated)

Latest MCRB, NGNE, TERN, and RNAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.29	N/A	N/A	N/A	N/A	N/A
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A
5/8/2025	Q1 2025	RNAC Cartesian Therapeutics	-$0.61	-$0.68	-$0.07	-$0.68	$0.69 million	$1.10 million
5/8/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	-$0.26	+$0.03	-$0.26	N/A	N/A
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MCRB Seres Therapeutics	N/A	2.11	2.11
NGNE Neurogene	N/A	21.03	21.03
RNAC Cartesian Therapeutics	N/A	12.34	12.34
TERN Terns Pharmaceuticals	N/A	30.89	30.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MCRB Seres Therapeutics	59.34%
NGNE Neurogene	52.37%
RNAC Cartesian Therapeutics	86.95%
TERN Terns Pharmaceuticals	98.26%

Insider Ownership

Company	Insider Ownership
MCRB Seres Therapeutics	4.70%
NGNE Neurogene	9.92%
RNAC Cartesian Therapeutics	60.30%
TERN Terns Pharmaceuticals	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable
NGNE Neurogene	90	14.26 million	12.85 million	Optionable
RNAC Cartesian Therapeutics	64	25.95 million	10.30 million	Optionable
TERN Terns Pharmaceuticals	40	87.34 million	86.03 million	Not Optionable

MCRB, NGNE, TERN, and RNAC Headlines

Recent News About These Companies

Terns Pharmaceuticals CEO & Director Acquires 98% More Stock

July 4, 2025 | finance.yahoo.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Purchases $39,300.00 in Stock

June 30, 2025 | marketbeat.com

Terns pharmaceuticals CEO Burroughs buys $90k in shares

June 27, 2025 | investing.com

Rivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

June 26, 2025 | fiercebiotech.comF

Insider Buying: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CEO Buys 23,314 Shares of Stock

June 25, 2025 | marketbeat.com

Terns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - Nasdaq

June 24, 2025 | nasdaq.com

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - Morningstar

June 24, 2025 | morningstar.comM

Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing

June 23, 2025 | medpagetoday.comM

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

June 23, 2025 | globenewswire.com

Population-Level Weight Loss Seen With Primary Care Protocol

June 21, 2025 | medscape.comM

SG Americas Securities LLC Purchases 380,489 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

June 18, 2025 | marketbeat.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Buys $19,750.00 in Stock

June 17, 2025 | insidertrades.com

Insider Buying: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Buys 5,000 Shares of Stock

June 16, 2025 | marketbeat.com

Andrew Gengos Buys 10,000 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

June 16, 2025 | marketbeat.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

June 14, 2025 | marketbeat.com

NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies | DelveInsight

June 13, 2025 | theglobeandmail.com

3 Penny Stocks Wall Street Sees With 243% Upside

June 11, 2025 | 247wallst.com

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 29, 2025 | globenewswire.com

Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential

May 27, 2025 | investing.com

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 14, 2025 | globenewswire.com

Why Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 11.67%

May 10, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
Top 3 Silver Picks to Watch as Bull Market Gains Steam
By Chris Markoch | June 18, 2025
View Top 3 Silver Picks to Watch as Bull Market Gains Steam
D-Wave Goes International With South Korea Partnership
By Nathan Reiff | June 23, 2025
View D-Wave Goes International With South Korea Partnership
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off

MCRB, NGNE, TERN, and RNAC Company Descriptions

Seres Therapeutics NASDAQ:MCRB

$11.60 +0.75 (+6.91%)

Closing price 07/8/2025 04:00 PM Eastern

Extended Trading

$11.66 +0.06 (+0.56%)

As of 07/8/2025 07:38 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Neurogene NASDAQ:NGNE

$20.28 +0.78 (+4.00%)

Closing price 07/8/2025 04:00 PM Eastern

Extended Trading

$20.30 +0.02 (+0.07%)

As of 07/8/2025 06:42 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Cartesian Therapeutics NASDAQ:RNAC

$11.30 +0.53 (+4.92%)

Closing price 07/8/2025 04:00 PM Eastern

Extended Trading

$11.01 -0.29 (-2.56%)

As of 07/8/2025 06:14 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Terns Pharmaceuticals NASDAQ:TERN

$4.53 +0.53 (+13.25%)

Closing price 07/8/2025 04:00 PM Eastern

Extended Trading

$4.60 +0.06 (+1.43%)

As of 07/8/2025 07:56 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time